Envestnet Portfolio Solutions Inc. Boosts Stake in United Therapeutics Corporation $UTHR

Envestnet Portfolio Solutions Inc. grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 267.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,654 shares of the biotechnology company’s stock after purchasing an additional 2,660 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in United Therapeutics were worth $1,050,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. HB Wealth Management LLC grew its holdings in shares of United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 35 shares during the period. Hohimer Wealth Management LLC grew its holdings in shares of United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock worth $3,900,000 after purchasing an additional 37 shares during the period. Park Avenue Securities LLC grew its holdings in shares of United Therapeutics by 1.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 39 shares during the period. Applied Finance Capital Management LLC grew its holdings in shares of United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company’s stock worth $349,000 after purchasing an additional 40 shares during the period. Finally, Headlands Technologies LLC grew its holdings in shares of United Therapeutics by 1.5% during the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company’s stock worth $828,000 after purchasing an additional 40 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $433.34 on Friday. The business has a 50-day moving average of $385.69 and a 200 day moving average of $328.04. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $459.48. The stock has a market capitalization of $19.55 billion, a price-to-earnings ratio of 16.91, a price-to-earnings-growth ratio of 4.72 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter in the previous year, the business posted $5.85 EPS. The business’s quarterly revenue was up 11.7% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $436.60, for a total transaction of $4,802,600.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $16,058,584.60. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $440.35, for a total transaction of $9,907,875.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 292,435 shares of company stock worth $118,956,307. Company insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Bank of America increased their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Weiss Ratings restated a “hold (c+)” rating on shares of United Therapeutics in a report on Wednesday, October 8th. UBS Group raised their target price on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a report on Monday, September 29th. Finally, Royal Bank Of Canada initiated coverage on United Therapeutics in a report on Friday, September 26th. They set an “outperform” rating and a $569.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $457.21.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.